PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg
Biotronik, Inc. · Decision date Sep 17, 2026
What did the FDA approve?
On 2026-09-17, FDA recorded an approval decision for P950037/S291, a PMA supplement submitted by Biotronik, Inc. The supplement is classified as a Real-Time Process submission with the stated reason "Change Design/Components/Specifications/Material." The recorded statement describes approval for updated programmer software PSW 2601.U and NEO 2601.U.
The title field lists the software alongside several device names, including Amvia Sky and Amvia Edge pacemaker models; the source does not specify which listed components the change touches. The underlying device category is implantable pacemaker pulse-generator, specialty Cardiovascular, product code DXY. This action covers the supplement's recorded scope only, not a new approval of the whole system. The source provides no documents, so clinical or labeling details of the change remain unknown.
Readers should not infer performance, safety or labeling consequences from the decision code alone; the absence of supporting documents limits interpretation.
FDA approval order statement
approval for updated programmer software PSW 2601.U and NEO 2601.U
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 17, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P950037/S291
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- Decision code
- APPR
- Decision date
- Sep 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: implantable pacemaker Pulse-generator.
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P950037 · Original PMA
DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS
P950037/S291 received
Application receipt date recorded by FDA.
P950037/S291 · FDA decision
Real-Time Process
P950037/S279 · Related supplement
Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-
P950037/S296 · Related supplement
Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-
P950037/S298 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos
P950037/S289 · Related supplement
BIOexpress
P950037/S299 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8
P950037/S300 · Related supplement
Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,
Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 11, 1996 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP950037/S289 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P950037/S291
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




